Skip to main content
Top
Published in: International Urology and Nephrology 2/2014

01-02-2014 | Urology - Original Paper

The influence of expertise of the surgical pathologist to undergrading, upgrading, and understaging of prostate cancer in patients undergoing subsequent radical prostatectomy

Authors: Attila Majoros, Attila Marcell Szász, Péter Nyirády, Eszter Székely, Péter Riesz, Attila Szendrői, Attila Keszthelyi, Janina Kulka, Imre Romics

Published in: International Urology and Nephrology | Issue 2/2014

Login to get access

Abstract

Purpose

The main objective of this retrospective study was to evaluate the influence of pathological experience in histological examination of prostate cancer (PCa) on preoperative understaging (UNS), undergrading (UNG), and upgrading (UPG).

Methods

Histopathological data of prostate biopsy (PB) and radical prostatectomy (RP) specimens of patients undergoing subsequent radical prostatectomy (n = 430) in our center were compared. Histological diagnoses of PB were provided either by corresponding academic pathology institute (Group 1: 322 patients) or by external (nonacademic) departments which had a lower number (≤100/year) of PCa histopathological evaluations (Group 2 108 patients). The rate of UNG, UPG, and UNS in both groups and also the effects of institutional learning curve were analyzed in terms of grading and staging.

Results

Significant difference was detected between Group 1 and Group 2 in average preoperative Gleason score (GS) values and in the rate of well, moderately, and poorly differentiated cancers as well. There was also a significant difference in the rate of UNG (29.1 vs. 56.5 %, p < 0.0001). The mean preoperative and postoperative GS in Group 1 was significantly lower in the first 50 than in the last 50 patients, but the rates of UNG, UPG, and UNS did not differ significantly between the groups.

Conclusions

The experience of pathologists has direct influence on grading concordance and on UNG and UPG, between PB and RP specimen; however, it has no significant effect on complete preoperative understaging. The bigger pathological experience improves the sensitivity of the histological diagnostic process.
Literature
1.
go back to reference Gleason DF (1996) Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. Urology 47(3):289–291PubMedCrossRef Gleason DF (1996) Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. Urology 47(3):289–291PubMedCrossRef
2.
go back to reference Cohen MS, Hanley RS, Kurteva T et al (2008) Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey clinic medical center experience and an international meta-analysis. Eur Urol 54(2):371–381PubMedCrossRef Cohen MS, Hanley RS, Kurteva T et al (2008) Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey clinic medical center experience and an international meta-analysis. Eur Urol 54(2):371–381PubMedCrossRef
3.
go back to reference Kuroiwa K, Shiraishi T, Naito S (2011) Gleason score correlation between biopsy and prostatectomy specimens and prediction of high-grade Gleason patterns: significance of central pathologic review. Urology 77(2):407–411PubMedCrossRef Kuroiwa K, Shiraishi T, Naito S (2011) Gleason score correlation between biopsy and prostatectomy specimens and prediction of high-grade Gleason patterns: significance of central pathologic review. Urology 77(2):407–411PubMedCrossRef
4.
go back to reference Djavan B, Kadesky K, Klopukh B, Marberger M, Roehrborn CG (1998) Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason score of radical prostatectomy specimens. Eur Urol 33(3):261–270PubMedCrossRef Djavan B, Kadesky K, Klopukh B, Marberger M, Roehrborn CG (1998) Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason score of radical prostatectomy specimens. Eur Urol 33(3):261–270PubMedCrossRef
5.
go back to reference King CR (2000) Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer 90:305–311PubMedCrossRef King CR (2000) Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer 90:305–311PubMedCrossRef
6.
go back to reference Wullich B, Füssel S, Grobholz R (2007) Optimized standards for prostate biopsy. Urologe A 46(6):675–682PubMedCrossRef Wullich B, Füssel S, Grobholz R (2007) Optimized standards for prostate biopsy. Urologe A 46(6):675–682PubMedCrossRef
7.
go back to reference Patel AR, Jones JS (2009) Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Curr Opin Urol 19(3):232–237PubMedCrossRef Patel AR, Jones JS (2009) Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Curr Opin Urol 19(3):232–237PubMedCrossRef
8.
go back to reference Heidenreich A, Bolla M, Joniau S et al (2011) Guidelines on prostate cancer. European Association of Urology Guidelines, pp 15–20. ISBN 978-90-79754-96-0 Heidenreich A, Bolla M, Joniau S et al (2011) Guidelines on prostate cancer. European Association of Urology Guidelines, pp 15–20. ISBN 978-90-79754-96-0
9.
go back to reference As Moussa, Li J, Soriano M, Klein EA, Dong F, Jones JS (2009) Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 103(1):43–48CrossRef As Moussa, Li J, Soriano M, Klein EA, Dong F, Jones JS (2009) Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 103(1):43–48CrossRef
10.
go back to reference Pinthus JH, Witkos M, Fleshner NE (2006) Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 176:979–984PubMedCrossRef Pinthus JH, Witkos M, Fleshner NE (2006) Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 176:979–984PubMedCrossRef
11.
go back to reference Bostwick DG (1994) Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 18:796–803PubMedCrossRef Bostwick DG (1994) Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 18:796–803PubMedCrossRef
12.
go back to reference D’Amico AV, Whittington R, Malkowicz SB et al (1995) A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 154:131–138PubMedCrossRef D’Amico AV, Whittington R, Malkowicz SB et al (1995) A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 154:131–138PubMedCrossRef
13.
go back to reference Münterer M, Epstein JI, Hernandez DJ et al (2008) Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53:767–776CrossRef Münterer M, Epstein JI, Hernandez DJ et al (2008) Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53:767–776CrossRef
14.
go back to reference Chun FK, Steuber T, Erbersdobler A et al (2006) Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 49(5):820–826PubMedCrossRef Chun FK, Steuber T, Erbersdobler A et al (2006) Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 49(5):820–826PubMedCrossRef
15.
go back to reference Kvåle R, Møller B, Wahlqvist R et al (2008) Concordance between Gleason score of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int 103:1647–1654PubMedCrossRef Kvåle R, Møller B, Wahlqvist R et al (2008) Concordance between Gleason score of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int 103:1647–1654PubMedCrossRef
16.
go back to reference Brookman-May S, May M, Wieland WF et al (2012) Should we abstain from Gleason score 2–4 in the diagnosis of prostate cancer? Results of a German multicentre study. Word J Urol 30(1):97–103CrossRef Brookman-May S, May M, Wieland WF et al (2012) Should we abstain from Gleason score 2–4 in the diagnosis of prostate cancer? Results of a German multicentre study. Word J Urol 30(1):97–103CrossRef
17.
go back to reference Brimo F, Schultz L, Epstein JI (2010) The value of mandatory second opinion pathology review of prostate needle biopsy interpretation before radical prostatectomy. J Urol 184(1):126–130PubMedCrossRef Brimo F, Schultz L, Epstein JI (2010) The value of mandatory second opinion pathology review of prostate needle biopsy interpretation before radical prostatectomy. J Urol 184(1):126–130PubMedCrossRef
18.
go back to reference Descazeaud A, Zerbib M, Flam T, Vieillefond A, Debré B, Peyromaure M (2008) Can pT0 stage of prostate cancer be predicted before radical prostatectomy? Eur Urol 50(6):1248–1252CrossRef Descazeaud A, Zerbib M, Flam T, Vieillefond A, Debré B, Peyromaure M (2008) Can pT0 stage of prostate cancer be predicted before radical prostatectomy? Eur Urol 50(6):1248–1252CrossRef
19.
go back to reference Burchardt M, Engers M, Müller M et al (2008) Interobserver reproducibility of Gleason grading: evaluation using prostate cancer tissue microarrays. J Cancer Res Clin Oncol 134(10):1071–1078PubMedCrossRef Burchardt M, Engers M, Müller M et al (2008) Interobserver reproducibility of Gleason grading: evaluation using prostate cancer tissue microarrays. J Cancer Res Clin Oncol 134(10):1071–1078PubMedCrossRef
20.
go back to reference Netto GJ, Eisenberger M, Epstein JI (2011) Interobserver variability in histologic evaluation of radical prostatectomy between central and local pathologist: findings of TAX 3,501 multinational clinical trial. Urology 77(5):1155–1160PubMedCentralPubMedCrossRef Netto GJ, Eisenberger M, Epstein JI (2011) Interobserver variability in histologic evaluation of radical prostatectomy between central and local pathologist: findings of TAX 3,501 multinational clinical trial. Urology 77(5):1155–1160PubMedCentralPubMedCrossRef
21.
go back to reference Mian BM, Lehr DJ, Moore CK et al (2006) Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urology 67(2):379–383PubMedCrossRef Mian BM, Lehr DJ, Moore CK et al (2006) Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urology 67(2):379–383PubMedCrossRef
22.
go back to reference Smith EB, Frieson HF Jr, Mills SE, Boyd JC, Theodorescu D (2002) Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer 94(8):2282–2287PubMedCrossRef Smith EB, Frieson HF Jr, Mills SE, Boyd JC, Theodorescu D (2002) Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer 94(8):2282–2287PubMedCrossRef
Metadata
Title
The influence of expertise of the surgical pathologist to undergrading, upgrading, and understaging of prostate cancer in patients undergoing subsequent radical prostatectomy
Authors
Attila Majoros
Attila Marcell Szász
Péter Nyirády
Eszter Székely
Péter Riesz
Attila Szendrői
Attila Keszthelyi
Janina Kulka
Imre Romics
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2014
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-013-0538-4

Other articles of this Issue 2/2014

International Urology and Nephrology 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine